White matter hyperintensities: a possible link between sarcopenia and cognitive impairment in patients with mild to

Xiaofen Weng1,2, Shanwen Liu1, Meng Li3

  • 1Department of Neurology, The Second Affiliated Hospital of Soochow University, 1055 San Xiang Road, Suzhou, 215004, Jiangsu, China.

PubMed
Abstract

Insights

White matter hyperintensities (WMH) in Alzheimer's disease (AD) are linked to muscle weakness and slower movement. These brain changes may connect physical decline with cognitive issues in AD patients.

Area of Science:

  • Neurology
  • Gerontology
  • Neuroimaging

Background:

  • Alzheimer's disease (AD) is often accompanied by sarcopenia, a loss of muscle mass and strength.
  • White matter hyperintensities (WMH) are frequently observed in AD patients, but their specific impact on sarcopenia is not well understood.

Purpose of the Study:

  • To investigate the association between regional white matter hyperintensity (WMH) volumes and sarcopenic parameters in individuals with Alzheimer's disease (AD).

Main Methods:

  • The study included 57 AD patients and 22 normal controls (NC).
  • Sarcopenic parameters such as appendicular skeletal mass index (ASMI), grip strength, 5-times sit-to-stand (5-STS) time, and gait speed were assessed.
  • Volumes of periventricular (PVH) and deep white matter hyperintensities (DWMH) were quantified using 3D-slicer software.

Main Results:

  • AD patients showed lower ASMI, slower gait speed, longer 5-STS time, and larger PVH and DWMH volumes compared to NC.
  • In AD subjects, WMH and PVH volumes correlated with cognitive impairment, especially executive function decline.
  • PVH volume was independently associated with 5-STS time and gait speed, while DWMH volume was independently associated with gait speed in AD patients.

Conclusions:

  • WMH volume is associated with cognitive decline and sarcopenic parameters in AD.
  • WMH may act as a link between sarcopenia and cognitive dysfunction in Alzheimer's disease.
  • Further research is needed to confirm these findings and explore potential interventions.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
143
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223